Sorry, you need to enable JavaScript to visit this website.
Search
hero
March 11, 2022

Study Shows Pfizer Vaccine Is Moderately Effective Against Omicron for Children 5-15

Body

Rockville, Md.  –  A new study by the Centers for Disease Control and Prevention (CDC) and Abt Global shows that the Pfizer-BioNTech COVID-19 vaccine is moderately effective against the Omicron variant for children ages 5-15. It reduced the risk of infection by 31% for children 5-11 and by 59% for children 12-15.

The Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT) study, which used real-world data, found that the vaccine was moderately effective against Delta and Omicron infection and that vaccinated children spent less time sick in bed than unvaccinated children with an Omicron infection.

The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms.

“Without regular weekly testing you will miss many infections, particularly for kids, who often have mild symptoms,” said Lauren Olsho, the PROTECT study’s principal investigator. “Other pediatric vaccine effectiveness studies relied on lab testing data or health records and generally captured only cases where a child had symptoms and received health care. With increased use of home rapid testing, studies like ours are needed to provide more comprehensive information on rates of infection and vaccine effectiveness.”

The CDC noted that the PROTECT study is among the largest studies with routine weekly COVID-19 testing, regardless of COVID-19-like symptoms. The CDC also said that the study may provide greater understanding of factors that can affect infection risk, such as socio-demographic characteristics, health information, frequency of close social contact, mask use, location, and local virus circulation. This insight provided more accurate estimates of vaccine effectiveness for preventing symptomatic or asymptomatic COVID-19 infection following a two-dose Pfizer-BioNTech mRNA vaccination series.

Researchers cautioned that the vaccinated children wore masks more often at school than the unvaccinated children, which could have affected the results. In addition, despite the sample size and diverse locations, it’s not clear if the results are generalizable for all 50 states.


About Abt Global
Abt Global is a global consulting and research firm that combines data and bold thinking to improve the quality of people's lives. We partner with clients and communities to advance equity and innovation—from creating scalable digital solutions and combatting infectious disease, to mitigating climate change and evaluating programs for measurable social impact. https://www.abtglobal.com

Contact: 
Stan Crock
stan_crock@abtassoc.com
(301) 347-5402

Read Our Latest News

Abt to Manage Australia’s Main Development Program for Fiji

The Australian Government recently awarded Abt Global a contract to manage a $90 million umbrella program covering half of Australia’s development assistance to Fiji.

Learn More
News

Abt Leads Decision Support for FCDO Land Governance Programme

Abt Global Britain has been appointed to lead the Decision Support Unit of the Land Facility, funded by the UK’s Foreign and Commonwealth Development Office.

Learn More
News

Public Warning: Recruitment Phishing Scam Impersonating Abt Global

Abt Global has become aware of a phishing scheme targeting individuals with fraudulent interview requests and job offers. Abt’s secure IT systems and private applicant information have not been compromised; scammers are impersonating Abt employees, using the company name and branding to mislead and engage potential job seekers in fake recruitment processes. Scammers might reference real job openings or describe fake opportunities that generally match individuals’ professional backgrounds, with the goal of establishing communication and eventually obtaining private financial information to defraud people. The Federal Bureau of Investigation and Federal Trade Commission warn that employment scams such as this are a growing cyber threat. Abt urges anyone who is contacted about employment opportunities to exercise caution and know that: All communication from Abt Global will be from an Abt employee using the @abtglobal.com email domain (e.g., recruiting@abtglobal.com). We do not use third-party recruiters.   Abt Global recruiters will only schedule interviews for candidates who have applied for a position through our secure portal.  You may view your application status through the applicant portal on Abt Global Careers.  No corporate or IT systems at Abt are affected by this scam. The scammers are using Abt’s logo and employee names to impersonate the company. You can directly contact us at recruiting@abtglobal.com with any questions or concerns. Abt is committed to ensuring the safety and security of our community. We caution individuals to be vigilant in protecting personal data and vetting communication with new contacts from any company. Do not respond or provide any personal information if contacted by someone claiming to represent a company to which you did not submit a job application or profile. This scam can be perpetrated against any business and individuals who recognize and trust its name. For information on Abt recruitment practices and policies, please visit our careers page or email recruiting@abtglobal.com. To report a scam, visit: https://reportfraud.ftc.gov/.   

Learn More
News

Abt is Top Private Firm in Gender Equality Report

Abt Tops 53 Private Firms in the 2024 Global Health 50/50 Gender Equality Report. 

Learn More
News